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Background: The intrapleural instillation of a sclerosing agent produces an inflammatory
process frequently followed by pain. The treatment can include the use of analgesics or
anti-inflammatory drugs. Previously, it was demonstrated (experimental studies) that corti-
coids and nonsteroidal anti-inflammatory drugs (diclofenac) reduce the inflammation and
fibrosis produced by talc but not by transforming growth factor-b or silver nitrate. The objec-
tive of this study was to determine whether parecoxib (COX-2 inhibitor) affects pleurodesis
induced by talc or silver nitrate.
Methods: 140 rabbits received intrapleural injection (2 mL) of 400 mg/kg of talc or 0.5% silver
nitrate. A subgroup of 70 animals received additional daily intramuscular parecoxib (1 mg/kg).
They were sacrificed at 4, 24, 48, 72 h or 7, 14, or 28 days after the procedure. The pleural
fluid was quantified; biochemical examinations (glucose, lactic dehydrogenase, and proteins)
and immunologic dosages (interleukin-8, vascular endothelial growth factor, and transforming
growth factor-b1) were analyzed in pleural fluid and blood. Finally, macro- and microscopic
pleura and lung studies were performed.
Results: Evaluation after 28 days demonstrated that parecoxib reduced pleural and pulmonary
inflammation but not pleural adhesions. The changes were observed precociously ðy72 hÞ and
were more evident after silver nitrate injection.
Conclusion: Systemic parecoxib injection does not interfere with talc or silver nitrate pleurod-
esis. These results suggest that use of COX-2 inhibitors can be considered and depending of the
results of other studies, recommended in human pleurodesis.
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Recurrent accumulation of liquid or air in the pleural space
represents one of the biggest challenges in the treatment
of pleural diseases. Chemical pleurodesis is frequently
indicated and performed by injecting a sclerosant agent
into the pleural space.1 The first step is the development of
an inflammatory process preceding a fusion of the pleural
membranes and the obliteration of the thoracic cavity.2
This procedure causes a painful process of varied
intensity whose treatment includes the administration of
analgesic and anti-inflammatory drugs that can interfere
with a cascade of events that start with inflammation and
culminate with collagen deposition and adhesion for-
mation.3e6 The relevance of this observation is clear when
we consider that some of the candidates for pleurodesis
may chronically use corticosteroids or even nonhormonal
anti-inflammatories. Among those, COX-2 inhibitors are
indicated in the management of pain, acute or chronic.7
Although, today we have several potent analgesic drugs,
many patients (as rheumatologic diseases) can be using
anti-inflammatories agents during the indication of
a pleurodesis.
Previously (experimental studies),4e6,8 we demonstrated
that corticosteroids, as well as sodium diclofenac, decrease
inflammation and fibrosis produced by intrapleural injec-
tion of talc or doxycycline, not interfering with pleurodesis
induced by TGF-b1 or silver nitrate.
In this context, the aim of this study is to answer
a practical question. Can the use of COX-2 inhibitors
decrease the efficacy of pleurodesis? If no interference is
observed, these drugs could represent a therapeutic tool in
pain control.
Material and methods
This study was developed in the Laboratory of Pleura of the
Heart Institute e Brazil (InCor), after the approval of our
institutional ethics committee.
A group of 140 New Zealand rabbits weighing 2.0e3.0 kg
was randomized into 4 groups and then subdivided
(5 animals) according to the time of sacrifice (4, 24, 48, 72 h
or 7, 14, or 28 days).
According to methodology previously described, the
animals were anesthetized with 35 mg/kg of hydrochloride
ketamine and 5 mg/kg of hydrochloride Xylazine (intra-
muscular) and prepared for aseptic surgery. A 19-gauge
needle attached to a 5-mL syringe containing the sclerosant
was inserted through the skin and thoracic muscles, at
approximately 1 cm of the parasternal line, between the
sixth and seventh intercostal space. The plunger of the
syringe was removed, and the needle was slowly advanced
until it reached the pleural space, where the subatmo-
spheric intrapleural pressure allowed the fluid to enter
spontaneously into the pleural cavity.9e11
The animals received (right hemithorax) 400 mg/kg of
talc or 0.5% silver nitrate, both in a total volume of 2 mL.
The injected talc is asbestos-free [Mg6(Si8O20) (OH)4] of
‘‘mixed size’’ (Magnesita, BA, Brazil), routinely used for
pleurodesis. It contains particles of varied size (mean:
25.4 mm; range: 6.4e50.5 mm); only 10% of particles aresmaller than 6.66 mm. The noninjected hemithorax (left)
was used as the control. In the group of rabbits receiving
parecoxib, the medicine was injected intramuscularly
(1 mg/kg), 24 h before the procedure, daily during the first
7 days, and weekly until the end of the experiment (28
days).
According to the defined times, the animals were
euthanized by an IV pentobarbital (40 mg/kg) injection
into the marginal ear vein. Immediately, blood samples
were collected, and a 21-gauge needle was inserted
through the diaphragm to aspirate the pleural fluid.11 The
collected fluids were centrifuged and separated for
biochemical analysis by automatized methods (glucose,
proteins, and lactic dehydrogenase) and immunologic
dosage (ELISA method) for interleukin-8 (IL-8), trans-
forming growth factor-b1 (TGF-b1), and vascular endothe-
lial growth factor (VEGF) analysis. In sequence, the thorax
was removed en bloc, and the lungs were expanded with
60 mL of 10% formalin and submerged in this solution for at
least 48 h. After this period, each pleural cavity was
exposed by using the method previously described by our
group.9,10 Finally, the thorax was opened, and a researcher
blinded to the treatment (LRT) evaluated the presence of
macroscopic pleural adhesions and collected fragments
from the pleura and pulmonary parenchyma for later
microscopic analysis.
Pleural adherence grades were established by the
following scores: (0) normal pleural space; (1) 1e3 small
adherences; (2) over 3 adherences, where lung can easily
be separated from the thorax; (3) generalized adhesions
(showing areas where the lung could only be separated
from the thoracic wall with difficulty), and (4) complete
obliteration of the pleural space by adhesions.
The pleura and lung parenchyma fragments were pro-
cessed, stained (hematoxylineeosin), and evaluated for the
presence of inflammation (inflammatory cells as neutro-
phils, eosinophils, neovascularization and fibrin) and
fibrosis (mononuclear and fibroblasts cells and fibrosis)
(graded from 0 e normal to 4 e marked changes). The
microscopic analysis was done by an experienced examiner
(LA) blinded to the treatment.9,10
Statistical analysis
A Sigma Stat 3.5 (System software e CA, USA) program was
used, and the results are reported as mean and SD.
Statistical significance was determined via a t test and
ManneWhitney rank-sum test. Differences were considered
significant at p< 0.05.
Results
Pleural fluid volume
In the animals receiving talc, the volume of pleural fluid
was similar, independent of COX-2 administration, except
in the evaluation performed 72 h after the procedure, when
a reduction was observed in the animals treated with the
anti-inflammatory (15.4 4.8 vs 6.4 2.7 mL; pZ 0.006).
After 7 days, the volume was minimal or absent in both
groups (0.7 1.6 vs 0.0 0.0 mL) (Fig. 1).
Figure 1 Effect of COX-2 inhibitor on pleural fluid volume and biochemical examinations after intrapleural talc (TL) or silver
nitrate (SN).
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sively, reaching the highest value at 72 h. In any of the
times considered, differences due to parecoxib treatment
were observed (Fig. 1).
Biochemical analysis
Total protein (PT) values in pleural fluid suggest, at all
times, the presence of an exudate (>3 g/dL). Lactic
dehydrogenase levels (DHL) were high in both pleural fluid
and blood (pleura/serum> 0.6), characterizing an exuda-
tive process. No differences between groups were found
(Fig. 1).
Cytokine evaluation
Rabbits receiving talc maintained stable levels of IL-8. No
differences between blood and pleural fluid were observed.
Four hours after the intrapleural silver nitrate injection,
IL-8 levels increased; after 24 h, a reduction was observed.
Evaluations performed from 4 to 48 h showed values
significantly higher in the groups that did not receive the
COX-2 treatment (Fig. 2).
VEGF, in the pleural fluid, increased progressively in the
first 72 h of the study, the levels were statistically lower in
the animals receiving talc and COX-2 (pZ 0.027). VEGF
levels observed in the pleural fluid, in all groups and at all
times, were higher than those obtained from blood
(Fig. 2).
TGF-b1 levels obtained from pleural liquid and blood
were similar throughout the study. Significant reduction
after 48 h of the intrapleural injection were observed in the
group treated with the anti-inflammatory, independent of
the sclerosant used (Fig. 2).Anatomopathological exams
Results obtained are shown in Fig. 3. The left hemithorax
(control) in all animals received a 0 score.
Macroscopically, the effect of the treatment with the
COX-2 inhibitor was observed transitorily in the animals
that received talc. A reduction in pleural adhesions was
noted after 48 (pZ 0.032), 72 h (pZ 0.048) and 7 days
(pZ 0.008). From the second week on and at the final
evaluation (28 days), no differences were observed. In the
silver nitrate group, no differences were observed.
Microscopically, the inflammation due to talc instilla-
tion was discrete. In the first 48 h, no differences were
characterized due to COX-2 administration. We observed
a reduction in the pleura (72 h: pZ 0.05; 7 days:
pZ 0.038; and 14 days: pZ 0.004) and in the pulmonary
parenchyma (72 h: pZ 0.032; 7 days: pZ 0.008; and 14
days: pZ 0.032) related to the COX-2 treatment. After 28
days, the inflammation was discrete in both, pleura and
lung.
Similar results were observed with silver nitrate. Pleural
inflammation was discrete up to 72 h, with no differences
due to the parecoxib treatment. From this time, pleural
inflammation increased; however, a significant reduction
was observed after 7 (pZ 0.004), 14 (pZ 0.002), and 28
days (pZ 0.011) due to COX-2 administration. The lung
parenchyma inflammation showed a similar pattern, with
statistical differences after 72 h (pZ 0.032), and 7
(pZ 0.008), 14 (pZ 0.032), and 28 days (pZ 0.005).
Pleural fibrosis became evident after 7 days (2.2 0.3)
of talc instillation and after 72 h (2.5 0.5) of silver nitrate
instillation. Treatment with COX-2 resulted in a reduction
in fibrosis after 72 h (p< 0.001) and 7 days (pZ 0.032) of
the silver nitrate injection.
Figure 2 Effect of COX-2 inhibitor on IL-8, VEGF, and TGF levels (pleura and blood) after intrapleural talc (TL) or silver
nitrate (SN).
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This study demonstrates that systemic administration of
parecoxib interferes with the inflammatory process that
develops in the pleural space after the injection of the
sclerosing agent (talc or silver nitrate), but does not reduce
the intensity of pleurodesis. It is important to note that this
fact was verified with the talc recommended to induce
pleurodesis, which contained mixed particles (90%
>6.6 mm) being effective and well tolerated and also
producing few local and systemic collateral effects.12
The sclerosing agent when introduced into the pleural
space damages the mesothelial cells, triggering an inflam-
matory process characterized by a neutrophilic exudate.2
The initial changes culminate in the development of
adhesions between the visceral and parietal pleura, oblit-
erating the virtual pleural space. Several factors modulate
these reactions including the degree of injury, the ability of
mesothelial cells and fibroblasts to secrete collagen, and
the balance between metalloproteinases and plasminogen
activators. In addition, the relationship among inflamma-
tion, cytokines, and fibrinolysis should be considered.2,8 As
the duration, extension, and intensity of inflammationestablished in the pleural space influence the final outcome
of pleurodesis, the use of anti-inflammatory agents can
inhibit this process, consequently reducing the pleural
adhesions. These findings have been previously docu-
mented in experimental studies,5,8 demonstrating that the
administration of anti-inflammatory drugs (corticosteroids
or diclofenac) reduces the effectiveness of pleurodesis
induced by talc. Conversely, another study6 showed that
the systemic administration of corticosteroids does not
interfere with pleurodesis induced by the intrapleural
injection of the transforming growth factor TGF-b1, as well
as the use of diclofenac in pleurodesis induced by silver
nitrate.8
The extrapolation of these results to humans raises the
question of whether previous or concomitant parecoxib
treatment compromises pleurodesis intensity, interfering
with the control of pneumothorax or pleural effusion.
The mechanisms involved in inflammation are complex.
It is interesting to observe, in this study, that talc or silver
nitrate instilled into the pleural space determined (acute
phase), a similar pleural exudate (Light’s criteria13), whose
inflammatory characteristics were more evident in the first
24 h. No changes in the volume of fluid accumulated were
Figure 3 Effect of COX-2 inhibitor on gross and microscopic analysis after intrapleural talc (TL) or silver nitrate (SN).
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inflammatory drug.
It is known that intrapleural instillation of a sclerosant
causes significant effects not confined to the pleural cavity;
systemic repercussion is observed according to the agent
used.14,15 This study confirms this fact, showing that talc
and silver nitrate increase cytokine serum levels, demon-
strating the presence of a systemic inflammatory process
with predominance in the pleural space.
The importance of interleukin-8 in the development of
pleural inflammation has been established. The immediate
increase (4 h) and the posterior decrement (24 h) of pleural
fluid IL-8 should be observed. In this study, the highest
levels were observed acutely in the pleural effusion after
intrapleural silver nitrate. Noteworthy is the reduction
after parecoxib treatment of IL-8 pleural and blood levels
in animals receiving silver nitrate but not in those injected
with talc.
The vascular endothelial growth factor levels increased
substantially in pleural fluid and discretely in blood. The
relationship between VEGF and the volume of pleural fluid
should be noted; the superposition of the curves suggests
the value of this angiogenic cytokine in pleural fluid accu-
mulation. Besides the participation in the initial inflam-
matory process stimulating the activation of other
mediators and facilitating inflammatory cell migration, it is
important in promoting vascular permeability.6,16
Finally, transforming growth factor (TGF-b1) increased
during all study period with similar levels in serum and
pleural fluid. It is a multifunctional cytokine with significant
fibrotic action modulating the deposition of connective
tissue and immune reactions.6,16 An experimental study
showed its importance in the development of pleurodesis;
when injected into the pleural space, it is not influenced by
anti-inflammatories.6The pleural injury observed after instillation of scle-
rosant agents and the interaction with anti-inflammatory
drugs demonstrate the complexity of the mechanisms
involved. The laboratory analyses express part of the
process while the final findings are represented by
the cellular and architectural changes in the pleura and in
the lung, more strongly observed after silver nitrate
instillation. However, a clear reduction in cellular afflux
occurs in parecoxib-treated groups, indicating a minor
inflammatory response in both pleura and pulmonary
parenchyma.
In this context, pleural fibrosis was higher in the silver
nitrate groups. Although collagen deposition had been
reduced in the acute phase of the animals treated with
silver nitrate and parecoxib, this drug did not compromise
the presence or the degree of macroscopic adhesions
present in all evaluations. Curiously, in the animals injected
with talc, parecoxib did not change the microscopic fibrosis
nor the volume accumulated in the pleural space, preco-
ciously. The reduction of the macroscopic adhesions
observed in the first days did not interfere in the develop-
ment or in the final result of pleurodesis.
A central question refers to the methodology. The
anti-inflammatory drug was administered daily for 7 days
and subsequently once a week until the end of the study
(28 days). This plan is based on clinical practice; the use
of anti-inflammatories in the induction of pleurodesis has
one single purpose, to relieve pain. During the first days,
both the pain and the inflammation are more
pronounced, justifying the schedule used. Another point
to be discussed could be the dose used daily instead
twice a day as in the clinical practice. Although we have
been used parecoxib once a day, due to be less invasive
for the animal, the dose administrated was the maximum
recommended.
600 L.R. Teixeira et al.Finally, the study has an evident clinical implication; the
extrapolation of these results suggests considering the use
of COX-2 inhibitor anti-inflammatories in patients with
pneumothorax or recurrent pleural effusion undergoing
pleurodesis. The significance of this observation should be
emphasized because many patients, who are candidates for
pleurodesis, use these anti-inflammatories routinely. Clin-
ical studies should be encouraged to define the analgesic
prescription and the degree of interference in the intensity
of pleurodesis.
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